A new study in France found that hydroxychloroquine provides no benefit for COVID-19 patients.

The French researchers looked at 181 COVID patients with pneumonia, given either standard of care alone or hydroxychloroquine in addition to standard of care.

They found that taking hydroxychloroquine at 600mg per day did not reduce admissions to intensive care or deaths after 21 days from hospital admission. It also did not increase survival in those without acute respiratory distress syndrome (ARDS).